MedTrace Logo

Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006

NCT02428608 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 570

Last updated 2019-04-24

Study results available
· View outcomes & findings →

Summary

The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in adult subjects.

Conditions

  • Glabellar Frown Lines

Interventions

BIOLOGICAL

DWP-450 (Botulinum purified neurotoxin, Type A)

Botulinum toxin, Type A

Sponsors & Collaborators

  • PPD Development, LP

    collaborator INDUSTRY

  • Evolus, Inc.

    lead INDUSTRY

Principal Investigators

  • Rui Avelar, MD · Evolus, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-10-31
Completion
2016-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02428608 on ClinicalTrials.gov